Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L-MYC allelotype in renal cell carcinoma

J C Presti1, J Hinckley, V E Reuter

  • 1Department of Urology, University of California, San Francisco 94143-0738, USA.

Cancer Genetics and Cytogenetics
|May 1, 1996
PubMed
Summary

The L-MYC allelotype, a genetic marker, was investigated for its prognostic value in renal cell carcinoma (RCC). This study found no correlation between L-MYC allelotypes and patient outcomes, suggesting it lacks clinical utility in RCC prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Reply by Authors.

The Journal of urology·2020
Same author

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.

European radiology·2015
Same author

Morphological measurement of neurotoxic injury in the peripheral nervous system: preparation of material for light and transmission electron microscopic evaluation.

Current protocols in toxicology·2012
Same author

Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database.

Prostate cancer and prostatic diseases·2011
Same author

Comparative genomic hybridization.

Methods in molecular medicine·2011

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • The L-MYC restriction fragment-length polymorphism (RFLP) has been proposed as a prognostic indicator in various cancers.
  • Specifically, the smaller L-MYC allele (S) was suggested to correlate with a worse prognosis compared to the larger allele (L) in lung, breast, and kidney cancers.
  • However, recent studies have questioned its significance, particularly in lung cancer.

Purpose of the Study:

  • To evaluate the prognostic significance of the L-MYC allelotype in a cohort of patients with renal cell carcinoma (RCC).
  • To determine if L-MYC allelotype can predict clinicopathologic parameters and clinical outcomes in RCC patients.

Main Methods:

  • DNA was extracted from tumor and normal tissues of 59 RCC patients who underwent radical nephrectomy.

Related Experiment Videos

  • EcoR1 restriction digests were performed, and Southern blotting was used with an L-MYC probe to determine allelotypes (L-L, L-S, S-S).
  • Statistical analysis (chi-squared test) was employed to correlate allelotypes with pathologic parameters and clinical outcomes.

    • Main Results:

    • The L-MYC allelotype did not show any significant correlation with any of the evaluated pathologic parameters in RCC patients.
    • No association was found between L-MYC allelotypes and the likelihood of disease recurrence.
    • The study found no clinical utility for L-MYC allelotype in predicting outcomes for patients with renal cell carcinoma.

    Conclusions:

    • The L-MYC allelotype does not serve as a prognostic marker in renal cell carcinoma.
    • Its clinical utility in predicting disease recurrence or correlating with pathologic features in RCC is not supported by this study.
    • Further research may be needed to explore other genetic markers for RCC prognosis.